Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Liposomal Doxorubicin|DRUG: Docetaxel
Sponsor: SCRI Development Innovations, LLC
Collaborators: Ortho Biotech, Inc.|Aventis Pharmaceuticals